0000000000471968

AUTHOR

Jens Ricke

showing 3 related works from this author

Imaging standardisation in metastatic colorectal cancer: a joint EORTC-ESOI-ESGAR expert consensus recommendation

2022

Background: Treatment monitoring in metastatic colorectal cancer (mCRC) relies on imaging to evaluate the tumor burden. Response Evaluation Criteria in Solid Tumors (RECIST) provide a framework on reporting and interpretation of imaging findings yet offer no guidance on a standardized imaging protocol tailored to mCRC patients. Imaging protocol heterogeneity remains a challenge for the reproducibility of conventional imaging endpoints and is an obstacle for research on novel imaging endpoints. Patients and methods: Acknowledging the recently highlighted potential of radiomics and artificial intelligence (AI) tools as decision support for patient care in mCRC, a multidisciplinary, internatio…

PROTOCOLCancer ResearchPositron emission tomographyArtificial intelligenceConsensusBEVACIZUMABMedizinImagingCancer -- ImagingHumansCRITERIAColon (Anatomy) -- Cancer -- TomographyComputed tomographyScience & TechnologyRadiomicsRectal NeoplasmsAbdomen -- Radiography -- Case studiesColon (Anatomy) -- Cancer -- TreatmentReproducibility of ResultsAbdomen -- Radiography -- StandardsOPEN-LABELColorectal cancerArtificial intelligence Standardisation Colorectal cancer Computed tomography Imaging Positron emission tomography RadiomicsOncologyColonic NeoplasmsSURVIVALStandardisationLife Sciences & Biomedicine
researchProduct

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

2016

Contains fulltext : 165965.pdf (Publisher’s version ) (Closed access) Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and speciali…

0301 basic medicineOncologymedicine.medical_specialtyEvidence-based practiceBevacizumabColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Guidelines as Topiccolorectal cancerRare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]03 medical and health scienceschemistry.chemical_compoundClinical practice guidelines; Colorectal cancer; Consensus; ESMO; Hematology; Oncology0302 clinical medicineGuia de Práctica ClínicaInternal medicineBiomarkers TumormedicineHumansMolecular Targeted TherapyNeoplasm MetastasisIntensive care medicineTipiracilNeoplasias Colorrectais/tratamentoFOLFOXIRIbusiness.industryESMO; clinical practice guidelines; colorectal cancer; consensusCancerHematologyESMOPrognosismedicine.diseaseDebulkingChemotherapy regimendigestive system diseases3. Good health030104 developmental biologyPractice GuidelineOncologychemistryColorectal Neoplasms/therapyconsensus030220 oncology & carcinogenesisColorectal Neoplasmsbusinessclinical practice guidelinesclinical practice guidelinemedicine.drug
researchProduct

Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the ran…

2019

Background: Secondary resection of initially unresectable colorectal cancer liver metastases (CRLM) can prolong survival. The added value of selective internal radiotherapy (SIRT) to downsize lesions for resection is not known. This study evaluated the change in technical resectability of CRLM with the addition of SIRT to FOLFOX-based chemotherapy. Methods: Baseline and follow-up hepatic imaging of patients who received modified FOLFOX (mFOLFOX6: fluorouracil, leucovorin, oxaliplatin) chemotherapy with or without bevacizumab (control arm) versus mFOLFOX6 (with or without bevacizumab) plus SIRT using yttrium-90 resin microspheres (SIRT arm) in the phase III SIRFLOX trial were reviewed by thr…

Malemedicine.medical_specialtyTime FactorsHepatic resectionTreatment outcomeAntineoplastic Agents030230 surgeryMicrosphereClinical study03 medical and health sciences0302 clinical medicinemedicineHepatectomyHumansNeoplasm MetastasisChirurgieLiver imagingRetrospective Studiesbusiness.industryIndividual participant dataLiver NeoplasmsFollow up studiesPatient dataOriginal ArticlesMiddle AgedTreatment Outcome030220 oncology & carcinogenesisFamily medicineHPBLower GISurgeryOriginal ArticleFemaleRadiotherapy AdjuvantbusinessColorectal NeoplasmsTomography X-Ray Computed:Ciencias de la Salud::Oncología [Materias Investigacion]Follow-Up Studies
researchProduct